<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931253</url>
  </required_header>
  <id_info>
    <org_study_id>1602-01</org_study_id>
    <nct_id>NCT02931253</nct_id>
  </id_info>
  <brief_title>Metformin as an Upstream Therapy in Atrial Fibrillation</brief_title>
  <official_title>Metformin as an Upstream Therapy in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Guthrie Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Guthrie Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if the study drug metformin will help patients who are
      overweight and have atrial fibrillation. This study aims to see if metformin helps patients
      stay in normal sinus rhythm after a catheter ablation.

      Metformin is investigational for use in patients with atrial fibrillation. Metformin is
      approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes
      Mellitus. Metformin is used with a proper diet and exercise program to control high blood
      sugar, and has been shown to help people lose weight. This study aims to look at the effects
      of metformin on weight loss and heart rhythm in patients with atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issue: Enrollment expectation not met
  </why_stopped>
  <start_date type="Actual">April 11, 2017</start_date>
  <completion_date type="Actual">July 10, 2018</completion_date>
  <primary_completion_date type="Actual">July 10, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Maintain Sinus Rhythm</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants who maintain sinus rhythm, normal heart rhythm by electrocardiogram (ECG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Hospitalization related to arrhythmic events or medication side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Antiarrhythmic Medications</measure>
    <time_frame>6 months</time_frame>
    <description>Total count of participants on anti-arrhythmic medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Requiring Repeat Ablations</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Average change in BMI from baseline to 6 month.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change from baseline to 6 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thromboembolic Events</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>Number of participants who have a thromboembolic event from baseline to 6 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weight Loss</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Weight change from baseline to 6 months.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Metformin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care - ablation only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
    <arm_group_label>Metformin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All individuals diagnosed with Atrial Fibrillation and choosing to undergo a rhythm
             control strategy at Robert Packer Hospital with a BMI â‰¥ 27 will be eligible for the
             study. All subjects must be able to understand and willing to sign a written informed
             consent document.

        Exclusion Criteria:

          -  Individuals who are already taking metformin or other antidiabetic medications
             including insulin, have a diagnosis of diabetes, have a known allergy or FDA-labeled
             contraindication to taking metformin, eGFR below 30 mL/min per 1.73 m2 or other
             clinical diagnosis of advanced renal disease,, have acute or chronic metabolic
             acidosis (serum bicarbonate &lt;22 mEq/L), have a history of significant alcohol use (&gt;2
             drinks/day on average), have a history of hepatic dysfunction (serum bilirubin 1.5X
             greater than the upper limit of normal), have a history of New York Heart Association
             (NYHA) Class III or IV heart failure, or are pregnant will be excluded from the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Guthrie Clinic</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2016</study_first_posted>
  <results_first_submitted>October 8, 2019</results_first_submitted>
  <results_first_submitted_qc>June 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2020</results_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/53/NCT02931253/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study terminated prior to meeting enrollment target. Enrollment rate slower than expected.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin Group</title>
          <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Standard of care - ablation only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin Group</title>
          <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Standard of care - ablation only</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="4"/>
                    <measurement group_id="B2" value="65" spread="3"/>
                    <measurement group_id="B3" value="66" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Maintain Sinus Rhythm</title>
        <description>Number of participants who maintain sinus rhythm, normal heart rhythm by electrocardiogram (ECG)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Maintain Sinus Rhythm</title>
          <description>Number of participants who maintain sinus rhythm, normal heart rhythm by electrocardiogram (ECG)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Hospitalization</title>
        <description>Hospitalization related to arrhythmic events or medication side effects</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Hospitalization</title>
          <description>Hospitalization related to arrhythmic events or medication side effects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Antiarrhythmic Medications</title>
        <description>Total count of participants on anti-arrhythmic medications</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Antiarrhythmic Medications</title>
          <description>Total count of participants on anti-arrhythmic medications</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Requiring Repeat Ablations</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Requiring Repeat Ablations</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI</title>
        <description>Average change in BMI from baseline to 6 month.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI</title>
          <description>Average change in BMI from baseline to 6 month.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread=".8"/>
                    <measurement group_id="O2" value="1.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c</title>
        <description>Change from baseline to 6 month</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <description>Change from baseline to 6 month</description>
          <units>percent glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".1" spread=".14"/>
                    <measurement group_id="O2" value=".15" spread=".1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thromboembolic Events</title>
        <description>Number of participants who have a thromboembolic event from baseline to 6 months</description>
        <time_frame>from baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thromboembolic Events</title>
          <description>Number of participants who have a thromboembolic event from baseline to 6 months</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Weight Loss</title>
        <description>Weight change from baseline to 6 months.</description>
        <time_frame>baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin Group</title>
            <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Standard of care - ablation only</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Loss</title>
          <description>Weight change from baseline to 6 months.</description>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="6.3"/>
                    <measurement group_id="O2" value="-.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin Group</title>
          <description>Metformin 500 mg daily initiated 6 weeks prior to scheduled ablation.
Metformin increased to 2000 mg daily (1000 mg twice a day) as tolerated over the initial 3 weeks.
Metformin: Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Standard of care - ablation only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pramod Deshmukh, MD</name_or_title>
      <organization>The Donald Guthrie Foundation for Education and Research</organization>
      <phone>570 887 2284</phone>
      <email>Pramod.Deshmukh@guthrie.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

